Ending the Arms Race: Ten Priorities for Fixing the Commercial Model

The drug industry has seen a massive shift in who influences prescription, payment, and consumption decisions. But corporate capabilities and tactics haven’t kept pace with these new market realities.

More from In Vivo Archive

More from In Vivo